GlassScriptPhysician profile
Sergio Alejandro Chevere
NPI 1295384295
$1,456.91
in general payments reported to CMS, 2019-2025
12 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $330 · 2023: $506 · 2024: $369 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.64 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $272.83 | 2022-2024 | Eliquis, Reblozyl |
| Janssen Pharmaceuticals, INC | $219.61 | 2022-2024 | Xarelto |
| Boston Scientific Corporation | $216.08 | 2021-2023 | |
| Abbvie INC. | $159.91 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Pbg Puerto Rico LLC | $152.06 | 2021-2024 | |
| Terumo Medical Corporation | $117.15 | 2025 | Access |
| Actelion Pharmaceuticals US, INC. | $94.99 | 2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $89.22 | 2021-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $72.02 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.45 | 2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $21.74 | 2021 | |
| Medtronic, INC. | $15.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Chevere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.